BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» FDA Approves Seattle Genetics' Adcetris for Two Lymphomas
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
FDA Approves Seattle Genetics' Adcetris for Two Lymphomas
Aug. 22, 2011
By
Trista Morrison
No Comments
Proving it can indeed beat deadlines when it wants to, the FDA issued a surprise approval of Seattle Genetics Inc.'s Adcetris (brentuximab vedotin) for two kinds of lymphoma late Friday afternoon – more than a week ahead of the Aug. 30 PDUFA date.
BioWorld